Fluoroquinolones are the most frequently prescribed antimicrobial agents in the United States. Fluoroquinolone- and multidrug-resistant bacteria are emerging infectious disease agents of worldwide concern and E. coli is an important human pathogen and excellent model organism. The long-term goals of the Zechiedrich laboratory are to determine how bacteria respond to and resist antimicrobial agents and to use this knowledge both to prolong the usefulness of current drugs and to aid in the design of new therapeutic protocols to help prevent and combat fluoroquinolone- and multidrug-resistant bacterial infections. The goals of this competing renewal proposal are to determine the (i) regulation, (ii) cellular roles, and (iii) molecular mechanisms of the multidrug efflux pumps, and the (iv) genetic alterations and (v) selection mechanisms that cause increased drug MICs in patient isolates. With thousands of characterized and uncharacterized fluoroquinolone- and multidrug-resistant E. coli patient isolates and the accompanying patient data, >9 million patient visits/year in the Texas Medical Center, and the strength of the combined expertise of the investigators, the goals will be achieved with the following Specific Aims: (1) Understand the interplay between and molecular mechanisms of the efflux pumps important for fluoroquinolone-resistance in E. coli;and (2) Identify molecular mechanisms, mutant selection mechanisms, and genetic pathways to fluoroquinolone- and multidrug-resistance in E. coli clinical isolates.
These Specific Aims will be achieved by three highly inter-related approaches: (i) A molecular approach will determine the transcriptional relationships among the fluoroquinolone efflux pumps and their regulators using quantitative reverse- transcription PCR first in defined mutant strains and then in fluoroquinolone-resistant E. coli clinical isolates;(ii) A computational approach will uncover evolutionarily related regions of the efflux pumps indicative of functionality;and (iii) A genomic approach using cost effective sequencing technologies will identify relevant heritable variations that correlate with the drug-resistance of the clinical isolates. These approaches are tied together using bioinformatics and data management infrastructures.

Public Health Relevance

With few new antimicrobial agents being developed, we must work to preserve those used currently. Excellent bioavailability, low toxicity and, in general, low resistance frequency, make the fluoroquinolones an important drug class to maintain in the physician's arsenal. Results from the proposed translational research will aid in the prescription practices of physicians and in the design of new therapeutic protocols to combat drug-resistant bacterial infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI054830-09
Application #
8322046
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Korpela, Jukka K
Project Start
2003-04-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
9
Fiscal Year
2012
Total Cost
$387,338
Indirect Cost
$139,838
Name
Baylor College of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Chou, Andrew; Nuila, Ricardo E; Franco, Luis M et al. (2016) Prevalence of hypervirulent Klebsiella pneumoniae-associated genes rmpA and magA in two tertiary hospitals in Houston, TX, USA. J Med Microbiol 65:1047-8
Irobalieva, Rossitza N; Fogg, Jonathan M; Catanese Jr, Daniel J et al. (2015) Structural diversity of supercoiled DNA. Nat Commun 6:8440
Pandey, Naresh; Nobles, Christopher L; Zechiedrich, Lynn et al. (2015) Combining random gene fission and rational gene fusion to discover near-infrared fluorescent protein fragments that report on protein-protein interactions. ACS Synth Biol 4:615-24
Carlson-Banning, Kimberly M; Chou, Andrew; Liu, Zhen et al. (2013) Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS One 8:e69646
Swick, Michelle C; Evangelista, Michael A; Bodine, Truston J et al. (2013) Novel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical Isolates. PLoS One 8:e65961
Singh, Renu; Swick, Michelle C; Ledesma, Kimberly R et al. (2012) Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 56:1680-5
Catanese Jr, D J; Fogg, J M; Schrock 2nd, D E et al. (2012) Supercoiled Minivector DNA resists shear forces associated with gene therapy delivery. Gene Ther 19:94-100
Zechiedrich, Lynn (2012) Editorial comment to genome-wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of Escherichia coli. Int J Urol 19:368-9
Fogg, Jonathan M; Randall, Graham L; Pettitt, B Montgomery et al. (2012) Bullied no more: when and how DNA shoves proteins around. Q Rev Biophys 45:257-99
Zhao, N; Fogg, J M; Zechiedrich, L et al. (2011) Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells. Gene Ther 18:220-4

Showing the most recent 10 out of 26 publications